Neuro-ectodermal tumours

Since its first reported use in humans in 1981 [1], 131I-meta-iodobenzylguanidine (MIBG) has been used with success for the scintigraphic diagnosis of a variety of neuroendocrine tumours [2]. Derived from the neural crest, many of these tumours maintain the characteristic features of these cells, such as an active uptake-1 mechanism at the cell membrane and neurosecretory storage granules in the cytoplasm, which are responsible for the specific uptake and retention of MIBG.